Newsletter Signup | Community
Cancer Connect - Treatment of Recurrent Multiple Myeloma
Stem Cell Transplant remains a major component in the treatment of newly diagnosed multiple myeloma.
Empliciti combined with Revlimid or Pomalyst delays progression and prolongs survival in recurrent multiple myeloma.
Addition of Darzalex™ to either Revlimd or Velcade based treatment regimens delays recurrence and prolongs survival.
Amgen releases initial data on AMG 420 Immunotherapy and the initial results in multiple myeloma look very good
Dr. Craig Hofmeister, MD guest-moderated on CancerConnect for a question-and-answer session in the Multiple Myeloma
New Antibody that targets CD74 on myeloma cells gets nod from FDA to proceed.
UK doctors identify a new target for treating Multiple Myeloma: